KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Gains from Sales and Divestitures (2018 - 2025)

ClearPoint Neuro's Gains from Sales and Divestitures history spans 6 years, with the latest figure at $617218.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures changed N/A year-over-year to $617218.0; the TTM value through Sep 2025 reached $617218.0, changed N/A, while the annual FY2024 figure was $212583.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $617218.0 at ClearPoint Neuro, up from $129434.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.0 million in Q3 2021 and bottomed at $12996.0 in Q1 2025.
  • The 3-year median for Gains from Sales and Divestitures is $617218.0 (2025), against an average of $820005.6.
  • The largest YoY upside for Gains from Sales and Divestitures was 271.96% in 2021 against a maximum downside of 169.06% in 2021.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $2.0 million in 2021, then tumbled by 89.49% to $212583.0 in 2024, then surged by 190.34% to $617218.0 in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Gains from Sales and Divestitures are $617218.0 (Q3 2025), $129434.0 (Q2 2025), and $12996.0 (Q1 2025).